ASCENTAGE PH.GRP SP.ADR/4
ASCENTAGE PH.GRP SP.ADR/4
Share · US04390B1052 · AAPG · A40ZYR (XNMS)
Overview Financial Indicators
26,36 EUR
0,84 % 0,22 EUR
Frankfurt (XNAS) · Current prices and charts at MoneyPeak
10.06.2025 16:15

Current Prices from ASCENTAGE PH.GRP SP.ADR/4

ExchangeTickerCurrencyLast TradePriceDaily Change
XNAS: NASDAQ
NASDAQ
AAPG
USD
10.06.2025 16:15
30,13 USD
29,88 USD
+0,84 %

Rendimiento

Día Semana Mes 3 meses 6 meses 1 año 5 años
0,64 % 8,56 % 22,15 % 44,61 % 47,05 % 50,34 % 58,84 %

Perfil de la empresa para ASCENTAGE PH.GRP SP.ADR/4 Acción

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through dual inhibition of the Bcl-2 and Bcl-xL proteins for the treatment of small-cell lung cancer, non-small cell lung cancer, neuroendocrine tumor, and non-Hodgkin's lymphoma. In addition, the company is developing APG-1387, a small molecule inhibitor of apoptosis proteins for advanced solid tumors and chronic HBV infection; APG-2449, an oral inhibitor of FAK, ROS1, and ALK kinases; APG-5918, an orally available and selective embryonic ectoderm development inhibitor; APG-265, a MDM2 protein degrader; and UBX1967/1325, which are Bcl-2 inhibitors. In addition, it is also involved in medical research and development; clinical development; clinical trial operation; venture capital investment; rental services; and science and technology promotion services. The company has collaboration relationships with biotechnology and pharmaceutical companies; and research institutions. Ascentage Pharma Group International was founded in 2009 and is headquartered in Suzhou, China.

Datos de la empresa

Nombre ASCENTAGE PH.GRP SP.ADR/4
Empresa Ascentage Pharma Group International
Símbolo AAPG
Sitio web https://www.ascentage.cn
Mercado principal XNMS Frankfurt
WKN A40ZYR
ISIN US04390B1052
Tipo de valor Acción
Sector Healthcare
Industria Biotechnology
CEO Dr. Dajun Yang M.D., Ph.D.
Capitalización de mercado 2 Mrd.
País China
Moneda EUR
Empleados 0,6 T
Dirección Suzhou Industrial Park, 215000 Suzhou
Fecha de OPV 2025-01-24

Kennungs-Wechsel

Datum Von Zu
27.01.2025 AAPGV AAPG

Ticker Symbole

Name Symbol
Frankfurt 36X0.F
NASDAQ AAPG

Weitere Aktien

Investoren die ASCENTAGE PH.GRP SP.ADR/4 die halten, haben auch folgende Aktien im Depot:
DE VOLKSBANK 21/26 MTN
DE VOLKSBANK 21/26 MTN Anleihe
PNC FINANCIAL SERVICES GROUP INC
PNC FINANCIAL SERVICES GROUP INC Aktie
Die Finanzplattform MoneyPeak trackt und analysiert Investitionen und Portfolios. Vom Wertpapier-Depot bis zum Crypto-Kauf.
Nützlich, simpel und kostenlos. Aktien, ETF, ETC, ETN, Indizes, Fonds, Anleihen, Zertifikate, Währungen, Optionen, Bezugsrechte.
Impressum Datenschutz Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025